Top

Published in:

Open Access 01-12-2014 | Research

Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis

Authors: Harold Kim, Susan Waserman, Jacques Hébert, Michael Blaiss, Harold Nelson, Peter Creticos, Amarjot Kaur, Jennifer Maloney, Ziliang Li, Hendrik Nolte

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2014

Abstract

Background

Currently accepted therapies for ragweed allergy in North America consist of pharmacotherapy and subcutaneous allergen immunotherapy injections to treat symptoms. Allergen immunotherapy not only reduces symptoms and the need for pharmacotherapy but has also been shown to have disease-modifying potential. Recently, ragweed immunotherapy administered via sublingual allergen tablet has been approved in North America for treatment of allergic rhinitis with and without conjunctivitis.

Methods

This was an analysis of pooled data for a prespecified subgroup of Canadian subjects from two multicentre, randomized, double-blind placebo-controlled trials of ragweed sublingual tablet (SLIT-T; 6 and 12 Amb a 1-U of Ambrosia artemisiifolia) in patients aged ≥18y, with ragweed-induced allergic rhinoconjunctivitis (AR/C) with or without asthma. Randomized subjects used once-daily ragweed SLIT-T or placebo for at least 12 weeks before the ragweed season and for up to 52 weeks post-randomization. The primary efficacy endpoint was the total combined score (TCS) based on the sum of AR/C daily symptom score (DSS) and daily medication score (DMS) averaged over the peak season. Treatment effects on TCS, DSS, and DMS in the entire season were also assessed. Adverse events (AEs) were monitored to assess safety.

Results

337 Canadian subjects were randomized in the two trials. During the peak season, ragweed SLIT-T 6 and 12 Amb a 1-U significantly reduced TCS by 26% (difference, -2.46 score point; p = .0009) and 40% (difference, -3.75 score point; p < .0001), respectively. In the overall population (N = 961), TCS reductions with 6 and 12 Amb a 1-U were 20% and 23%, respectively (both p < .001). Clinically meaningful reductions in entire-season TCS in Canadians were similar to those during peak ragweed season. Dose-dependent reduction of DSS and DMS was also observed for ragweed SLIT-T 6 and 12 Amb a 1-U during the peak season and the entire season. Ragweed SLIT-T was well tolerated in Canadian subjects and the overall population. Adverse events were generally mild to moderate and transient, occurring early in treatment; no systemic allergic reaction/anaphylaxis was noted.

Conclusion

Ragweed SLIT-T is an effective form of immunotherapy that provides symptomatic efficacy of AR/C with a favorable risk profile in Canadian and overall populations.

Trial registration

Clinicaltrials.gov identifiers NCT00783198 and NCT00770315.

Available only for authorised users

Oswalt ML, Marshall GD: Ragweed as an example of worldwide allergen expansion. Allergy Asthma Clin Immunol. 2008, 4 (3): 130-135. 10.1186/1710-1492-4-3-130.PubMedCentralCrossRefPubMed

Breton M-C, Garneau M, Fortier I, Guay F, Louis J: Relationship between climate, pollen concentrations of Ambrosia and medical consultations for allergic rhinitis in Montreal, 1994–2002. Sci Total Environ. 2006, 370 (1): 39-50. 10.1016/j.scitotenv.2006.05.022.CrossRefPubMed

Simard M-J, Benoit DL: Effect of repetitive mowing on common ragweed (Ambrosia artemisiifolia L.) pollen and seed production. Ann Agric Environ Med. 2011, 18 (1): 55-62.PubMed

Ziska L, Knowlton K, Rogers C, Dalan D, Tierney N, Elder MA, Filley W, Shropshire J, Ford LB, Hedberg C, Fleetwood P, Hovanky KT, Kavanaugh T, Fulford G, Vrtis RF, Patz JA, Portnoy J, Coates F, Bielory L, Frenz D: Recent warming by latitude associated with increased length of ragweed pollen season in central North America. Proc Natl Acad Sci U S A. 2011, 108 (10): 4248-4251. 10.1073/pnas.1014107108.PubMedCentralCrossRefPubMed

An Atlas of Airborne Pollen Grains and Common Fungus Spores of Canada. 1978, [http://archive.org/stream/atlasofairbornep00bass#page/n7/mode/2up]

Chan-Yeung M, Anthonisen NR, Becklake MR, Bowie D, Sonia Buist A, Dimich-Ward H, Ernst P, Sears MR, Siersted HC, Sweet L, Van Til L, Manfreda J: Geographical variations in the prevalence of atopic sensitization in six study sites across Canada. Allergy. 2010, 65 (11): 1404-1413. 10.1111/j.1398-9995.2010.02399.x.CrossRefPubMed

Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, Nelson M, Weber R, Bernstein DI, Blessing-Moore J, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph C, Schuller DE, Spector SL, Tilles S, Wallace D: Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011, 127 (1): S1-S55. 10.1016/j.jaci.2010.09.034.CrossRefPubMed

Lichtenstein LM, Norman PS, Winkenwerder WL: A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies. Ann Intern Med. 1971, 75 (5): 663-671. 10.7326/0003-4819-75-5-663.CrossRefPubMed

Donovan JP, Buckeridge DL, Briscoe MP, Clark RH, Day JH: Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Ann Allergy Asthma Immunol. 1996, 77 (1): 74-80. 10.1016/S1081-1206(10)63483-7.CrossRefPubMed

10.

Small P, Kim H: Allergic rhinitis. Allergy Asthma Clin Immunol. 2011, 7 (Suppl 1): S3-10.1186/1710-1492-7-S1-S3.PubMedCentralCrossRefPubMed

11.

Rhodes BJ: Patient dropouts before completion of optimal dose, multiple allergen immunotherapy. Ann Allergy Asthma Immunol. 1999, 82 (3): 281-286. 10.1016/S1081-1206(10)62609-9.CrossRefPubMed

12.

More DR, Hagan LL: Factors affecting compliance with allergen immunotherapy at a military medical center. Ann Allergy Asthma Immunol. 2002, 88 (4): 391-394. 10.1016/S1081-1206(10)62370-8.CrossRefPubMed

13.

Nolte H, Hébert J, Berman G, Gawchik S, White M, Kaur A, Liu N, Lumry W, Maloney J: Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol. 2013, 110 (6): 450-456.e4. 10.1016/j.anai.2013.03.013.CrossRefPubMed

14.

Creticos PS, Maloney J, Bernstein DI, Casale T, Kaur A, Fisher R, Liu N, Murphy K, Nekam K, Nolte H: Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol. 2013, 131 (5): 1342-1349.e6. 10.1016/j.jaci.2013.03.019.CrossRefPubMed

15.

Green BJ, Beezhold DH, Gallinger Z, Barron CS, Melvin R, Bledsoe TA, Kashon ML, Sussman GL: Allergic sensitization in Canadian chronic rhinosinusitis patients. Allergy Asthma Clin Immunol. 2014, 10 (1): 15-10.1186/1710-1492-10-15.PubMedCentralCrossRefPubMed

16.

Maloney J, Bernstein DI, Nelson H, Creticos P, Hebert J, Noonan M, Skoner D, Zhou Y, Kaur A, Nolte H: Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014, 112 (2): 146-153.e2. 10.1016/j.anai.2013.11.018.CrossRefPubMed

17.

Kette F, Smith W: Sublingual immunotherapy: allergen specific or placebo effect?. J Allergy Clin Immunol. 2011, 128 (2): 430-author reply 430–432CrossRefPubMed

18.

Murphy K, Bernstein D, Berman G, Creticos P, Gawchik S, Maloney J, Kaur A, Liu N, Nolte H: Assessing the efficacy of allergy immunotherapy tablet treatment: are local application-site reactions unblinding the trials and confounding efficacy measurements?. Ann Allergy Asthma Immunol. 2012, 109: A137-Abstract P346

19.

Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, Potter PC, Bousquet PJ, Cox LS, Durham SR, Nelson HS, Passalacqua G, Ryan DP, Brozek JL, Compalati E, Dahl R, Delgado L, van Wijk RG, Gower RG, Ledford DK, Filho NR, Valovirta EJ, Yusuf OM, Zuberbier T, Akhanda W, Almarales RC, Ansotegui I, Bonifazi F, Ceuppens J, Chivato T: Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. World Allergy Org J. 2009, 2 (11): 233-281. 10.1097/WOX.0b013e3181c6c379.CrossRef

20.

Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Ait-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA²LEN and AllerGen). Allergy. 2008, 63 (Suppl 86): 8-160.CrossRefPubMed

21.

André C, Perrin-Fayolle M, Grosclaude M, Couturier P, Basset D, Cornillon J, Piperno D, Girodet B, Sanchez R, Vallon C, Bellier P, Nasr M: A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis: evidence for a dose–response relationship. Int Arch Allergy Immunol. 2003, 131 (2): 111-118. 10.1159/000070926.CrossRefPubMed

22.

Bowen T, Greenbaum J, Charbonneau Y, Hebert J, Filderman R, Sussman G, Del Carpio J, Gold M, Keith P, Moote W, Cecchetto S, Cecchetto O, Sharp D, Broutin O, André C: Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2004, 93 (5): 425-430. 10.1016/S1081-1206(10)61408-1.CrossRefPubMed

23.

Skoner D, Gentile D, Bush R, Fasano MB, McLaughlin A, Esch RE: Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol. 2010, 125 (3): 660-666. 10.1016/j.jaci.2009.12.931. 666.e1–666.e4CrossRefPubMed

24.

Creticos PS, Esch RE, Couroux P, Gentile D, D'Angelo P, Whitlow B, Alexander M, Coyne TC: Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2014, 133 (3): 751-758. 10.1016/j.jaci.2013.10.041.CrossRefPubMed

Title: Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis
Authors: Harold Kim
Susan Waserman
Jacques Hébert
Michael Blaiss
Harold Nelson
Peter Creticos
Amarjot Kaur
Jennifer Maloney
Ziliang Li
Hendrik Nolte
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Allergy, Asthma & Clinical Immunology / Issue 1/2014
Electronic ISSN: 1710-1492
DOI: https://doi.org/10.1186/1710-1492-10-55

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis

Abstract

Background

Methods

Results

Conclusion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2014

Identification of the main allergen sensitizers in an Iran asthmatic population by molecular diagnosis

Th17/Treg ratio derived using DNA methylation analysis is associated with the late phase asthmatic response

Allopurinol desensitization with A 2 weeks modified protocol in an elderly patients with multiple comorbidities: a case report

Birth weight, gestational age, fetal growth and childhood asthma hospitalization

Allergic diseases in subjects under 18 years living with HIV

Two year effects of food allergen immunotherapy on quality of life in caregivers of children with food allergies